Physician profile
Spencer E Simon
NPI 1679536296
$95,396.67
in general payments reported to CMS, 2019-2025
25 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,021 · 2022: $1,326 · 2023: $723 · 2024: $2,540 · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Travel and Lodging: $20K · Consulting Fee: $14K · Food and Beverage: $9,752 · Honoraria: $520 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,468.00 |
| Travel and Lodging | $19,991.84 |
| Consulting Fee | $14,103.00 |
| Food and Beverage | $9,751.57 |
| Honoraria | $520.00 |
| Education | $215.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49,816.72 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $17,973.83 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $16,724.96 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,263.97 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,036.57 | 2021-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $990.98 | 2021-2025 | |
| Alkermes, INC. | $968.60 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $743.17 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $651.59 | 2021-2025 | Ingrezza |
| Uswm, LLC | $581.34 | 2021-2024 | Lucemyra, Zimhi |
| Takeda Pharmaceuticals U.S.A., INC. | $464.88 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $441.39 | 2021-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $342.56 | 2021-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $320.37 | 2021-2022 | |
| Indivior INC. | $274.56 | 2021-2025 | Perseris, Sublocade |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $148.72 | 2024-2025 | Loreev Xr |
| Tris Pharma INC | $146.40 | 2022-2024 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $125.65 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $117.99 | 2021-2022 | |
| Neos Therapeutics, LP | $92.49 | 2024-2025 | Adzenys Xr-Odt |
| Eisai INC. | $49.36 | 2021-2022 | |
| Corium, LLC | $47.17 | 2022-2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $39.94 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $21.87 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.